233 results about "Atopic dermatitis" patented technology

Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.

The invention belongs to the technical field of microorganisms, and discloses a bifidobacterium animalis subsp. Lactis XB02 strain capable of inhibiting pathogenic bacteria and improving inflammation, the preservation number of the bifidobacterium animalis subsp. Lactis XB02 strain is CGMCC (China General Microbiological Culture Collection Center) No.34942, and the preservation date is June 18, 2025. Meanwhile, the probiotic composition adopting the bacterial strain XB02 also comprises a lactobacillus rhamnosus XB01 bacterial strain. The XB02 strain disclosed by the invention has excellent bacteriostatic activity, especially for vibrio parahaemolyticus and gardneria; the atopic dermatitis symptom can be obviously improved; the intestinal mucosa permeability is reduced, and the intestinal barrier function is enhanced; and when the strain is combined with the XB01 strain for use, a synergistic sleep promoting effect is shown. The invention further provides a probiotic composition containing the strain, a preparation and application of the probiotic composition and the preparation in food, medicine or health care products.

Methods are provided for treating moderate to severe atopic dermatitis of the hands and / or feet in a subject. In one aspect, the methods include administering to the subject one or more doses of an interleukin-4 receptor (anti-IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

The application provides a drying method of Chuanxiong medicinal material and application of Chuanxiong or its extract in preparation of an external medicine for treating atopic dermatitis. The drying method of Chuanxiong medicinal material improves Chuanxiong processing efficiency, shortens processing period, obtains by-product Chuanxiong extract in addition to preparation of decoction pieces, reduces energy consumption and lowers production cost. The Chuanxiong essential oil and Chuanxiong extract are both composed of small molecule components, have good affinity to skin, are absorbed through skin quickly, can quickly relieve symptoms such as itching and skin damage caused by atopic dermatitis, and are natural, safe and free of side effects. Meanwhile, the small molecule components contained in the Chuanxiong essential oil and Chuanxiong extract have good lipophilicity, have softening effect on the thickened stratum corneum caused by atopic dermatitis, and are more conducive to drug absorption. In addition, the Chuanxiong essential oil and Chuanxiong extract are simple to prepare and low in price.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

This invention discloses a Litsea cubeba extract, its preparation method, and its applications, relating to the field of pharmaceutical compound technology. The Litsea cubeba extract has the structural formula shown in Formula I: (Formula I). ​​This Litsea cubeba extract is isolated from the Litsea cubeba plant. This novel compound can significantly inhibit NO production in an LPS-induced RAW264.7 cell inflammation model; alleviate the immune-inflammatory response in an in vitro 3D skin model of atopic dermatitis; inhibit epidermal thickening and repair skin barrier function; and reduce the inflammatory response by inhibiting the PI3K / Akt signaling pathway. It has clinical application potential in the treatment of atopic dermatitis and can be used to prepare anti-atopic dermatitis drugs, showing promising application prospects.

The application discloses a Qingjiang Aurantii Fructus extract with soothing and repairing effects on atopic dermatitis and application thereof, and a preparation method of the Qingjiang Aurantii Fructus extract comprises the following steps: A1, crushing Qingjiang Aurantii Fructus, adding water to soak, and then sterilizing; A2, inoculating probiotics in the solution after sterilization in step A1 to perform fermentation; A3, filtering the obtained fermentation liquor after sterilization, and purifying to obtain the Qingjiang Aurantii Fructus extract; wherein the probiotics are at least one selected from lactic acid bacteria, bacillus and yeast fungi. The Qingjiang Aurantii Fructus extract obtained by fermenting Qingjiang Aurantii Fructus with specific probiotics has significant soothing, repairing and anti-inflammatory effects, and has the soothing and repairing effects on atopic dermatitis in particular.

Compounds, compositions, and methods are provided for treating atopic dermatitis (AD) in patients in need.

The invention relates to a tetrapeptide of formula N-Palmitoyl-Lys-Thr-Phe-Lys, for use in the prevention and / or treatment of human atopic dermatitis (AD), as well as to a composition comprising at least said tetrapeptide and at least one physiologically acceptable excipient, for use in the prevention and / or treatment of human atopic dermatitis (AD).

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

The invention relates to an NEK7 inhibitor, a pharmaceutical composition and application of the NEK7 inhibitor. The NEK7 inhibitor has a structural formula as shown in a formula (I). The compound disclosed by the invention has good NEK7 inhibitory activity, and can be used for treating or preventing a plurality of inflammatory pathological diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout and the like) regulated by NLRP3 inflammasome.

The application discloses a traditional Chinese medicine extract with antibacterial, anti-inflammatory and antipyretic effects and an active component self-assembled nanomaterial of the traditional Chinese medicine extract and application, wherein the polygonum capitatum extract and the active component self-assembled nanomaterial have the effects of inhibiting bacteria and relieving inflammation and can be used for treating atopic dermatitis. The in-vitro bacteriostatic experiment and animal experiment results verify that the polygonum capitatum extract and the active component self-assembled nanomaterial have the effects of resisting bacteria and inflammation and can effectively treat atopic dermatitis.

The present invention provides an apparatus for managing atopic dermatitis based on a learning model and a method therefor. The method for managing atopic dermatitis according to the present invention includes the steps of: collecting, basic data including a patient's daily life factor, biometric factor, mental health factor, skin status factor, weather-related environmental factor, and an atopic dermatitis severity index based on the medical record; learning a weight for each detailed variable by applying, to a learning model, the relationship between the atopic dermatitis severity index and respective detailed variables for a plurality of factors; determining a reference value of the weight for selecting, as valid variables, N detailed variables for each factor; reconstructing the learning model by selecting, for each factor, N valid variables; and predicting the atopic dermatitis severity index by applying, to the reconstructed learning model, the currently corrected basic data of the patient to be analyzed.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

The present application provides a kind of microalgae source glycerol glucoside preparation and its preparation method and application, belong to medical technical field.The crude extract solution is obtained by low-osmotic extraction liquid extraction to salt stress algal mud, impurity is removed by filtration, and phycocyanin concentrated solution and glycerol glucoside containing permeate are obtained by membrane filtration separation, glycerol glucoside containing permeate is concentrated, bleaching and desalting, drying, and microalgae source glycerol glucoside is prepared, is mixed uniformly with gypenoside and bisabolol, and the mixture is prepared, after being embedded with oleic acid modified cholesterol and phospholipid to prepare modified liposome, mixed with chitosan solution and reacted, centrifuged, and the supernatant is discarded, and the solid is washed and dried to prepare microalgae source glycerol glucoside preparation.The present application realizes the technical effects of microalgae resource green low-carbon high-value utilization, product efficient purification, multi-target point synergistic anti-inflammatory and high transdermal absorption retention, and provides a kind of safe and effective, long-term use natural source new choice for treating atopic dermatitis externally.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

Provided are compounds, compositions and methods for treating atopic dermatitis (AD) in patients in need thereof.

The application discloses a kind of self-assembly hydrogel, preparation method and application, belong to material field.The application claims to protect a kind of self-assembly hydrogel, it is formed by glycyrrhizic acid, five gallate glucose and paeonol by molecular self-assembly;Wherein, the mass ratio of glycyrrhizic acid and five gallate glucose, paeonol is (10~60) :(1~8) :(2~8).The self-assembly hydrogel provided by the application is suitable for skin, raw material is natural, biocompatibility is good, mechanical and storage stability is excellent, can release paeonol and the transdermal effect is good, three components synergistically improve atopic dermatitis and other skin inflammation, and clinical value is high.In addition, the preparation process of the self-assembly hydrogel of the application is simple, can be prepared using conventional one-pot method, easy to produce.Therefore, the self-assembly hydrogel of the application has the prospect of developing into paeonol sustained-release delivery system, paeonol transdermal sustained-release preparation or skin inflammation treatment drug.

Provided herein are compounds having inhibitory activity toward the Janus Kinase 1 (JAK-1) enzyme, and which are useful as therapeutic and / or prophylactic agents. The compounds may be useful in treating inflammatory disorders in non-human mammals, for example, in treating canine atopic dermatitis. Also provided herein are methods for preparation of such compounds.

A method for treating pruritus in patients with atopic dermatitis (AD) and / or nodular prurigo (PN) is disclosed, comprising administering a therapeutically effective amount of at least one compound selected from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-carbonyl]-4-methyl-4-[4-(oxecyclobutane-3-yl)piperazin-1-yl]pent-2-enonitrile (rezabrutinib) and pharmaceutically acceptable salts thereof.

The invention discloses bifidobacterium animalis subsp. Lactis CCMXJ2003 as well as a composition and application thereof, and belongs to the technical field of microbial preparations. In order to screen a specific probiotic strain which can form efficient synergy with 2 '-fucosyllactose and has good viability and an immunoregulation function, and construct a precise micro-ecological intervention scheme aiming at atopic dermatitis immunopathology key links, the invention provides a microecological intervention method for the atopic dermatitis immunopathology key links. The invention provides the bifidobacterium animalis subsp. Lactis CCMXJ2003 capable of efficiently utilizing the 2 '-fucosyllactose, and an in-vivo experiment proves that the composition of the 2'-fucosyllactose and the bifidobacterium animalis subsp. Lactis CCMXJ2003 shows an obvious enhancement effect in the aspect of relieving the specific dermatitis; the compound has a wide application prospect in prevention and / or treatment of atopic dermatitis.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

To provide a compound in the manufacture of a medicament for treating diseases associated with overexpression or abnormal activation of JAK kinase and SYK kinase, including autoimmune diseases such as immune-mediated skin diseases (especially psoriasis, atopic dermatitis and SLE).SOLUTION: Provided is a compound of formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

The present invention relates to compounds of formula (I) with STAT6 inhibitory activity for use in methods of treatment of inflammatory or allergic diseases, such as e.g. atopic dermatitis.

This invention relates to a method for disease therapeutic target discovery and drug prediction based on multi-omics networks and deep learning models, belonging to the interdisciplinary field of bioinformatics and artificial intelligence drug discovery. The method includes: integrating genomic expression profiles and common molecular interaction data from disease and control groups to construct a candidate whole-genome network; refining the network based on expression profile data through systematic modeling and the AIC criterion to obtain the real molecular interaction network; extracting the core network using the master network projection method and identifying key targets through pathway analysis; predicting candidate drugs interacting with the targets using a pre-trained deep neural network model; and finally screening potential therapeutic drugs based on multi-dimensional criteria such as regulatory ability, sensitivity, and toxicity. This invention achieves a complete integration from disease mechanism analysis to drug prediction, and is particularly suitable for complex diseases such as atopic dermatitis. It can systematically discover precise targets and efficiently predict repositionable drugs, significantly improving R&D efficiency.